• Publications
  • Influence
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
  • M. Goetz, J. Rae, J. Ingle
  • Biology, Medicine
    Journal of clinical oncology : official journal…
  • 20 December 2005
In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with the previous observation that CYP3A5*3 variant was not associated with any of these clinical outcomes.
The genomic landscape of small intestine neuroendocrine tumors.
Sequencing-based analysis may provide provisional grouping of SI-NETs by therapeutic targets or deregulated pathways, and identified recurrently altered mechanisms of carcinogenesis: chromatin remodeling, DNA damage, apoptosis, RAS signaling, and axon guidance.
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
CYP2D6 metabolism, as measured by genetic variation and enzyme inhibition, is an independent predictor of breast cancer outcome in post-menopausal women receiving tamoxifen for early breast cancer.
The Hsp90 chaperone complex as a novel target for cancer therapy.
Early results from phase I studies indicate that 17-AAG administration results in an acceptable toxicity profile while achieving in vivo disruption of client proteins, and future directions for combinations of traditional antineoplastics with 17- AAG are discussed.
Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1.
CYP1A2 is the predominant P450 that catalyzes DTIC hepatic metabolism; CYP2E1 contributes to hepatic DTIC metabolism at higher substrate concentrations; and CYP1A1 catalyzes extrahepatic metabolism of DTIC.
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
A stepwise development of a nanoparticle-based targeted delivery system for in vitro and in vivo therapeutic application in pancreatic cancer and it is confirmed that the inhibition of tumor growth was due to targeted delivery.
Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
It is concluded that TMZ is well tolerated in this oral 5-day schedule with dose-limiting thrombocytopenia and that it has promising activity in glioma and melanoma.
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP 2D6 alleles was associated with better clinical outcomes and the absence of nonfunctional or reduced-function alleles with worse outcomes.
Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response
The a priori knowledge of the pharmacogenetic variation known to abrogate CYP2D6 enzyme activity may provide a means by which the hormonal therapy of breast cancer can be individualized.
A pharmacologic and toxicological study of amygdalin.
This small study indicates that amygdalin in the doses employed produces few clinical side effects, and a definite hazard of cyanide toxic reaction must be assumed, however, and possible long-term side effects remain unknown.